Abstract
Background: To assess effects of esomeprazole-based therapies and others (PPIs) on Helicobacter pylori eradication when co-administered with antibiotics. Goals: Using the terms ‘H. pylori eradication’ and ‘esomeprazole’, we searched Medline, Embase, and the Cochrane Library (2000–2005) and conducted a manual search of related Chinese journals to identify randomized controlled trials (RCTs) that compared the treatment effects of esomeprazole and other PPI therapies in patients with H. pylori infection. Results: Of the 75 articles screened, 11 RCTs including 2,159 subjects were included in the meta-analysis. The mean H. pylori eradication rates (intention-to-treat, ITT) with esomeprazole + antibiotics was 86%, a rate comparable with other PPI therapies, 81% (ITT); the odds ratio (OR) was 1.38 (95% CI = 1.09–1.75). A focused meta-analysis of 6 selected high-quality studies was produced an OR of this comparison that was closer to one (1.17, 95% CI = 0.89–1.54), with the results being statistically homogeneous. Sub-analysis that included only studies comparing different does of esomeprazole with omeprazole or pantoprazole did not reveal significant differences. No additional serious adverse events were reported. Conclusions: Esomeprazole-based triple therapy may effectively eradicate H. pylori infection and promote favorable outcome with good tolerance and offers comparable efficacy to omeprazole-based therapy.
Journal Section:
Review
References
1.
Consensus Proposal of Management Helicobacter pylori Infection (2003): Tongcheng Anhui. Chinese Medical Association Section of Digestive Disease. Chin J Dig 2004;24:126–127.
2.
Hassan-Alin M, Andersson T, Niazi M, Rohss K: A pharmacokinetic study comparing single and repeated oral doses of 20 and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 2005;60:779–784.
[PubMed]
3.
Song FJ, Altman DG, Glenny AM: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
[PubMed]
4.
Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, Tsay FW, Wu CJ, Lo CC, Tseng HH, Yamaoka Y, Chen JL, Lo GH: A prospective randomized trail of esomeprazole vs. pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005;100:2387–2392.
[PubMed]
5.
Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC, Wu JJ: Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005;21:283–288.
[PubMed]
6.
Chen YH, Wang WM, Wang H, Li HY: Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection. Di Yi Jun Yi Da Xue Xue Bao 2005;25:1045–1047.
[PubMed]
7.
Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D: Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004;38:503–506.
[PubMed]
8.
Miehlke S, Schneider-Brachert W, Bastlein E, Ebert S, Kirsch C, Haferland C, Buchner M, Neumeyer M, Vieth M, Stolte M, Lehn N, Bayerdorffer E: Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. Aliment Pharmacol Ther 2003;18:799–804.
[PubMed]
9.
Veldhuyzen Van Zanten S, Machado S, Lee J: One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1381–1387.
[PubMed]
10.
Maev IV, Kurilo AE, V’iuchnova ES, Shchekina MI: Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy. Ter Arkh 2003;75:23–26.
[PubMed]
11.
Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC, Labenz J, Argila CM De, Lind T, Treichel HC, Stubberod A, Cockeram A, Hasselgren G, Gothe L, Wrangstadh M, Sinclair P: One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000;14:1605–1611.
[PubMed]
12.
Tulassay Z, Kryszewski A, Dite P, Kleczkowski D, Rudzinski J, Bartuzi Z, Hasselgren G, Larko A, Wrangstadh M: One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001;13:1457–1465.
[PubMed]
13.
Zhang YT, Jiang Y, Li P: The comparison of esomeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori infection. Acad J Guangdong Pharmacy 2004;20:561–563.
14.
Xie SB: Esomeprazole-based triple therapy for Helicobacter pylori correlated peptic ulcer for 32 cases. Clin Drug 2005;14:76.
15.
Gisbert JP, Pajares JM: Systematic review and meta-analysis: is 1-week proton pump inhibitor based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 2005;21:795–804.
[PubMed]
16.
Vergara M, Vallve M, Gisbert JP, Calvet X: Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647–654.
[PubMed]
17.
Sauerland S, Seiler CM: Role of systematic reviews and meta-analysis in evidence-based medicine. World J Surg 2005;29:582–587.
[PubMed]
18.
Jadad AR, Moore A, Carrol D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996;17:1.
[PubMed]
19.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–789.
[PubMed]
20.
Madisch A, Bayerdoerffer E, Baestlein E, Consolazio A, Pica R, Rivera M, Palladini D, Nardi F, Paoluzi P: Seven-day triple therapy with esomeprazole, levofloxacin and amoxicillin is effective in patients with metronidazole- and clarithromycin-sensitive and -resistant H. pylori strains. Gastroenterology 2003;124:772.
21.
Miehlke S, Ebert S, Kirsch C, Haferland C, Buchner M, Neumeyer M, Vieth M, Stolte M, Lehn N, Bayerdorffer E: One-week triple therapy with esomeprazole, clarithromycin and metronidazole is highly effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance – a prospective randomized multicenter trial. Gastroenterology 2003;124:M1493.
22.
Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, Aponte-Rivera E, Marxuach-Cuetara AM, Rodriguez-Orengo JF, Fernandez-Carbia A: High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci 2005;50:634–639.
[PubMed]
23.
Gatta L, Perna F, Figura N, Ricci C, Holton J, D’Anna L, Miglioli M, Vaira D: Antimicrobial activity of esomeprazole vs. omeprazole against Helicobacter pylori. J Antimicrob Chemother 2003;51:439–442.
[PubMed]
24.
Oderda G, Marinello D, Lerro P, Kuvidi M, de’Angelis GL, Ferzetti A, Cucchiara S, Franco MT, Romano C, Strisciuglio P, Pensabene L: Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial. Helicobacter 2004;9:293–301.
[PubMed]
25.
Gisbert JP, Dominguez-Munoz A, Dominguez-Martin A, Gisbert JL, Marcos S: Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am J Gastroenterol 2005;100:1935–1940.
[PubMed]
26.
Hu FL, Jia JC, Li YL, Yang GB: Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer. J Int Med Res 2003;31:469–474.
[PubMed]
27.
Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM: Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists – their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:757–766.
[PubMed]
28.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.
[PubMed]
© 2006 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2006
You do not currently have access to this content.
